doi: 10.1016/j.clnesp.2022.08.023 470 LehtorantaLLatvalaSLehtinenMJ
In some embodiments, the formulations or composition described herein have a pH and osmolarity as described herein, and have a concentration of active pharmaceutical ingredient between about 0.1-about 70 mg/mL, between about 1 mg-about 70 mg/mL, between about 1 mg-about 50 mg/mL, between about 1 mg/mL and about 20 mg/mL, between about 1 mg/mL to about 10 mg/mL, between about 1 mg/mL to about 5 mg/mL, or between about 0.5 mg/mL to about 5 mg/mL of the active agent by volume of the formulation or composition
Metabolic regulation Used in research on the GH/IGF-1 axis and downstream metabolic and body-composition endpoints
Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism
Once punctured (if in a multi-dose vial), keep refrigerated and discard after the expiration or beyond-use date provided by the pharmacy
Body composition research One of the most important questions in obesity pharmacotherapy is whether weight loss preserves or degrades lean body mass